Collagen Peptides and Cellular Aging: a Randomized, Placebo-controlled Study on Telomere Length, Inflammation, Body Composition, and Functional Capacity in Adults 50-70 Years

What this Trial Is About

Researchers are studying whether taking collagen peptide supplements daily can help stabilize or lengthen telomeres and improve markers related to cellular aging in adults aged 50 to 70 years who have overweight and engage in low-to-moderate physical activity. This trial compares collagen peptides with a placebo to see if collagen affects aging markers such as telomere length, telomerase activity, inflammation, body composition, and functional health. Participants will take either collagen peptides or a placebo every day for 24 weeks. The study is randomized and double-blinded, with two groups receiving either collagen or a maltodextrin placebo. Study visits occur at the start, after 3 months, and after 6 months. At each visit, blood samples will be collected to measure telomere length and telomerase activity, as well as inflammation and oxidative stress markers. Body composition will be assessed using bioelectrical impedance, and participants will undergo tests of muscle strength and mobility, along with completing health and vitality questionnaires. During the trial, participants will attend three visits for blood draws and physical assessments. Researchers will monitor changes in telomere length, telomerase activity, DNA oxidation, inflammatory markers, body composition, muscle strength, and patient-reported outcomes like quality of life, fatigue, and sleep quality. The total participation time is 24 weeks, with detailed evaluations at baseline, 3 months, and 6 months to assess the effects of collagen peptide supplementation compared to placebo.

Collagen Peptides and Cellular Aging